

PRESS RELEASE

Bedfont Scientific strengthens its presence in the United States with the acquisition of its exclusive distributor coVita

Maidstone, United Kingdom, 13 October 2026 – Bedfont® Scientific Ltd. (“Bedfont” or the “Company”), a specialist in non-invasive breath analysis, today announces the acquisition of coVita, its long-standing and exclusive distributor in the United States. The transaction, supported by Keensight Capital (“Keensight”), one of the leading private equity firms dedicated to pan-European Growth Buyout^[1] investments, strengthens Bedfont’s presence in the US market and marks a new milestone in its international development.

Based in The Woodlands, Texas, coVita has been distributing Bedfont’s solutions in the United States for more than 16 years. Throughout this long-standing partnership, coVita has contributed to the deployment of Bedfont’s breath analysis technologies in the US market and has developed an in-depth understanding of the needs of healthcare professionals and clinical research stakeholders. The company also provides technical support, equipment calibration and user support services to specialist allergy and pulmonology networks, respiratory disease practices, outpatient clinics and clinical research organisations.

The combination will bring together Bedfont’s technological expertise with coVita’s knowledge of the US market and commercial infrastructure. It will enable Bedfont to strengthen its access to healthcare networks and clinical research in the United States, particularly through its NObreath® device for measuring fractional exhaled nitric oxide (FeNO[2]). It will also enhance collaboration in distribution, training and technical support, bringing Bedfont closer to US healthcare professionals. The founders of coVita will remain involved in the company’s development, helping to ensure continuity in relationships with customers and partners.

This acquisition is part of Bedfont’s international development strategy and reflects Keensight’s ambition to support its portfolio companies in accelerating their growth. Following its majority investment in Bedfont in 2025, Keensight is supporting a further stage in the company’s development, drawing on its expertise in the healthcare sector and its international network.

Jason Smith, CEO and Founder of Bedfont Scientific, said: *“Making non-invasive breath testing more accessible is at the heart of our mission. Building on our long-standing partnership with coVita will help us reach more healthcare professionals and researchers across the United States.”*

Jason Aversano and Daniel Sibus, co-founders of coVita, added: *“Our companies share the same commitment to supporting healthcare professionals. This combination creates new opportunities to grow our business while preserving the local expertise and customer relationships we have built together.”*

^[1] **Growth Buyout:** investment in profitable, private companies experiencing strong growth, in minority or majority positions, with or without leverage, using a flexible approach tailored to the needs of individual entrepreneurs, in order to finance organic growth projects, acquisition strategies or provide historic shareholders with liquidity.

^[2] **FeNO:** Fractional exhaled nitric oxide is a biomarker of airway inflammation used in the diagnosis and monitoring of asthma. It is measured non-invasively by analysing the concentration of nitric oxide in exhaled breath.

Nicolas Ulrich, Partner at Keensight Capital concluded: *“The acquisition of coVita represents an important milestone in Bedfont’s international growth strategy. Our role is to support the management team in identifying and implementing growth drivers that sustainably strengthen the company’s market position. This transaction brings together two complementary areas of expertise and will provide Bedfont with a strong local platform from which to accelerate its development in the US market, particularly in FeNO and clinical research.”*

About Bedfont Scientific

Bedfont Scientific is a global leader in non-invasive breath and gas analysis. Since 1976, the company has been dedicated to making breath analysis more accessible and reliable through innovative yet affordable technology. With a network of over 100 distributors worldwide, Bedfont’s devices help raise standards of care across both primary and secondary healthcare settings. Driven by a mission to advance patient care through innovation, Bedfont offers one of the most comprehensive portfolios in breath analysis: (i) NObreath[®] FeNO – a gold-standard biomarker for the diagnosis and management of asthma, (ii) Smokerlyzer[®] – carbon monoxide monitoring to support smoking cessation programs, (iii) Gastrolyzer[®] – hydrogen and methane breath testing to detect gastrointestinal disorders and food intolerances and (iv) Medi-Gas Check – medical pipeline testing to verify both the quality and quantity of gases administered to patients. By combining cutting-edge technology with affordability, Bedfont continues to set the benchmark for breath analysis worldwide, supporting better diagnosis, monitoring, and management of a wide range of conditions. www.bedfont.com

About coVita

coVita specializes in breath analysis technologies and medical diagnostic equipment. Based in The Woodlands, Texas, the company has operated as coVita for nearly 17 years, and its leadership has partnered with Bedfont Scientific for more than 28 years, bringing Bedfont’s non-invasive breath analysis devices to the US market. coVita supports healthcare professionals, hospitals, universities, research organizations and clinical research stakeholders in the use of breath analysis technologies, and provides training, technical assistance and user support services nationwide. www.covita.net

About Keensight Capital

Keensight Capital (“Keensight”), one of the leading European Growth Buyout firms, is committed to supporting entrepreneurs as they implement their growth strategies. With over 25 years of experience and more than €8bn of assets under management, Keensight Capital’s team of seasoned professionals leverages their differentiated private equity experience to invest in profitably growing companies generating revenues in the range of €10 million to €400 million. Drawing on its expertise in the Technology and Healthcare sectors, Keensight identifies the best investment opportunities in Europe and works closely with the management teams, providing capital, strategic guidance and operational support. Keensight operates in more than 90 countries across the globe with a presence in Paris, London, Boston, and Singapore. www.keensight.com

Press contacts

Keensight Capital

Servane Taslé, Communications Director – stasle@keensight.com +33 (0)7 56 25 49 51

Emily Slarko, Communications Manager – eslarko@keensight.com +33 (0)7 56 25 20 96

Headland Consultancy

Will Thomas – wthomas@headlandconsultancy.com +44 (0)77 7669 2746

Bedfont Scientific

Jemma Carter, Communications & Content Coordinator — Jemma@bedfont.com

coVita

Amanda Vaquera — bedfont@covita.net